Global private equity and venture capital news and research

Ampersand Capital exits lab business Viracor in $255m sale

3 Jul 2014

VIBT lab helixAmpersand Capital Partners has exited its majority stake in speciality testing lab Viracor-IBT Laboratories to Eurofins Scientific as part of a $255m sale.

The private equity firm created ViraCor in 2009 by merging two independent labs in Kansas City before adding on two more businesses through bolt-on deals.

VIBT provides highly-specialized, complex diagnostic tests available for infectious disease, immunology and allergy complications.

Mid-market focused Ampersand targets growth equity investments in the healthcare sector, and has managed $1bn in private equity partnerships.

In April it emerged that Ampersand had raised more than $100m towards its latest fund.

Ampersand has raised seven funds over the past 20 years, producing a 24 per cent pooled IRR.

Copyright ©2014 AltAssets

AltAssets Mobile App

To access the latest private equity news and stories download the new AltAssets mobile app from the

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2016